Amgen Reports post-marketing Data for Alectinib in Colorectal cancer

Amgen today announced post-marketing results for alectinib in patients with colorectal cancer. The study demonstrated that alectinib reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of colorectal cancer and support the continued development of alectinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.